Organised in conjunction with:

Friday 15 October 2021

Founded in 2009, Clovis Oncology is a commercial stage biotechnology company focused on acquiring, developing and commercializing cancer treatments in the United States, Europe and other international markets.

Development Programs Are Focused on Providing the Right Drug, to the Right Patient at the Right Time.

Clovis’ product development programs generally target specific subsets of cancer, and the Company seeks to simultaneously develop, with partners, for those indications that require them, diagnostic tools intended to direct a compound in development to the patients most likely to benefit from their use. Through these collaborations, Clovis has the flexibility to choose the most appropriate technology for each program, and the expertise to gain regulatory approvals and support global commercialization that will parallel Clovis’ regulatory and commercialization paths. Clovis believes this approach to precision medicine—to deliver the right drug to the right patient at the right time—represents the future of cancer therapy.

At Eisai, everything we do is dedicated to giving our first thought to patients and their families through our human health care (hhc) philosophy. We are the European hub of Tokyo-based Eisai Co. Ltd., forming part of a multinational team working across a global network of R&D facilities, manufacturing sites and marketing subsidiaries.  

Our collective passion and dedication to patient care is the driving force behind our efforts to discover and develop innovative medicines in a variety of therapeutic areas in which a high unmet medical need remains, including oncology and neurology.

Guerbet is a worldwide leader in medical imaging that has been supporting healthcare professionals since 1926. Guerbet offers a wide range of pharmaceutical products, medical devices, software and services for diagnostic and interventional imaging to improve the diagnosis and treatment of patients. A pioneer through more than 90 years in the field of contrast media with over 2,600 colleagues globally. Guerbet is continuously innovating with 10% of revenue dedicated to research and development across four centres in France, Israel and the United States.

HistoSonics is developing a non-invasive platform and novel sonic beam therapy utilizing the science of histotripsy, a novel mechanism of action that uses focused ultrasound to mechanically destroy and liquify targeted tissues at the cellular level. Utilizing advanced on-board imaging to target and personalize its therapy, histotripsy uses rapidly expanding and collapsing micro-bubbles to destroy targeted tissues, avoiding ionizing radiation, heat damage from thermal modalities, and incisions or needles from traditional treatments. Our mission and passion are to advance the novel science of histotripsy and its potential benefits, bringing meaningful and transformational change to physicians and their patients.

At IGEA we study the clinical application of physical stimuli to biological systems. IGEA is the leading company for Electrochemotherapy, a minimally invasive treatment combining a low dose of a chemotherapy drug and an electrical pulse (electroporation) applied directly to the cancer cells using specific multiple needle or individual needle electrodes. Our mission is to improve patients’ Quality of Life by developing and producing innovative, effective and safe therapeutic systems for clinical practice. Cliniporator® and Cliniporator® VITAE are the most advanced electroporation technologies for the treatment of tumour nodules located to the skin, subcutaneous tissue, parenchyma and bone.

At Ipsen, our licensed medicines and R&D cover a range of therapeutic areas. However, all are focused on curing disease and relieving suffering, hoping to bring real value to the healthcare community. Ipsen is committed to developing new treatments with the ability to improve and extend lives of those affected. Ipsen’s work in oncology currently focuses on several cancer types (including RCC, HCC, NET and prostate cancer) looking at where we can add benefit along every step of the treatment pathway and use targeted therapies to address conditions with high unmet needs.

The NEUWAVE™ Microwave Ablation System, now a part of the Ethicon™ portfolio of products, is the first intelligent ablation system and the only system that has it all. The versatile probe portfolio with multi-probe synchronized energy delivery allows physicians to tailor ablations with 1, 2 or 3 probes. In addition, the 17-gauge NEUWAVE™ PR probe is the only probe available with distal energy control to help protect non-target tissue. The unique computer-controlled system now includes Ablation Confirmation™ software, offering the only integrated in-procedure confirmation to help confirm probe placement and evaluate the technical success of your procedure. Build your ablation program with the first intelligent ablation system and the only system that has it all.

Lilly is a global healthcare leader uniting caring with discovery to deliver innovative medicines. Whether it's treating rare tumour types, leveraging precision medicine or discovering new ways to advance existing treatments, we're dedicated to making greater differences in lives of people living with cancer. 

Our purpose is to reimagine medicine to improve and extend people's lives. We use innovative science and technology to address some of society's most challenging healthcare issues. We discover and develop breakthrough treatments and find new ways to deliver them to as many people as possible. We also aim to reward those who invest their money, time and ideas in our company.

Sirtex Medical is a global healthcare business with offices in the US, Australia, Germany and Singapore, working to improve outcomes in people with cancer. Our current lead product is a targeted radiation therapy called SIR-Spheres® Y-90 resin microspheres. SIR-Spheres® Y-90 resin microspheres are a medical device used in Selective Internal Radiation Therapy (SIRT) for treatment of unresectable hepatocellular carcinoma (HCC) and unresectable metastatic liver tumors from primary colorectal cancer in patients refractory to or intolerant of chemotherapy. Learn more about Sirtex in our interactive virtual booth.

Terumo Interventional Systems provide a wide choice of products in our Interventional Oncology portfolio from Access with our extensive range of Progreat microcatheters which allow you to navigate distally and embolise reliably. Terumo’s coaxial system enables fast and smooth procedures with minimal preparation.  Our therapeutic options include HydroPearl & LifePearl for TACE procedure, Combination Therapy with LifePearl & TATO ablation. Radioembolisation is available with Quirem Scout & QuiremSpheres for SIRT treatment. We support BTACE with our innovative Occlusafe Microballoon Intervention – Terumo has the solution.  Terumo’s Learning Edge workshops allow clinicians to expand their range of procedures and we also offer Lunch & Learn sessions for you MDT teams.

UK Medical is a Sheffield based SME, we supply a range of interventional medical devices to the NHS and the private healthcare sector. We select proven, clinically effective devices that are not only cost effective, but also improve patient outcomes.

Visit our website: ukmedical.com
Email us: [email protected]
Tel: +44 (0) 114 268 8880

Saturday 16 October 2021

Sunday 17 October 2021